14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BHST vs PBM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Psyence Biomedical Ltd. Common Shares (PBM) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.9/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while BHST wins 4–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus PBM at $2.97 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: PBM earns the overall head-to-head edge with a stronger Unified Composite Score (63.9/100 BUY vs. BHST 58.2/100 HOLD) and 1.13β · 124% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile PBM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs PBM. Trailing 12-month operating profitability (BHST -18.0% vs PBM 0.0%) and valuation multiples (BHST N/M vs PBM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $12.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BHST vs PBM Key Questions & Quantitative Answers
As of Nov 20, 2026, Psyence Biomedical Ltd. Common Shares (PBM) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.9/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while BHST wins 4–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus PBM at $2.97 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: PBM earns the overall head-to-head edge with a stronger Unified Composite Score (63.9/100 BUY vs. BHST 58.2/100 HOLD) and 1.13β · 124% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile PBM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with PBM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus N/A for PBM. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PBM.
BHST screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas PBM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus PBM (-58.6% ROE) capital efficiency.
In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, PBM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.13β · 124% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.